Bone News and Research

RSS

High-resolution X-ray method can predict risk of re-operation in patients who receive new hip prosthesis

Between 5 and 30 percent of those who receive a new hip prosthesis will require a re-operation during their lifetime. New research shows that a high-resolution X-ray method can predict which patients have the greatest risk of re-operation.

22 Oct 2015

Melatonin and the circadian rhythm: an interview with Professor Kennaway, University of Adelaide

The production of melatonin is controlled by a part of the brain called the suprachiasmatic nucleus (SCN) and its timing fine-tuned by our exposure to light during the morning.

20 Oct 2015

Viking successfully completes safety, tolerability and pharmacokinetic study of VK5211 in elderly subjects

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class or best-in-class therapies for metabolic and endocrine disorders, today announced the successful completion of a short-term safety, tolerability, and pharmacokinetic study of VK5211 in healthy elderly subjects. VK5211, the company's lead program for muscle and bone disorders, is an orally available, non-steroidal selective androgen receptor modulator (SARM) being developed for the treatment of patients recovering from non-elective hip fracture surgery.

20 Oct 2015

Mordor Intelligence announces publication of ‘Global Sports Medicine Market’ report

Mordor Intelligence is pleased to announce the publication of the report on Global Sports Medicine Market on October 20, 2015. This report discusses the market in detail.

20 Oct 2015

TSRI researchers find way to change leukemia cells into leukemia-killing immune cells

Scientists at The Scripps Research Institute have found a way to change leukemia cells into leukemia-killing immune cells. The surprise finding could lead to a powerful new therapy for leukemia and possibly other cancers.

20 Oct 2015

Ember Therapeutics reports initial results from BMP-7 Phase II trial in patients with moderate osteoarthritis of the knee

Ember Therapeutics, Inc., a privately held, New York-based biopharmaceutical company that is developing targeted therapies for osteoarthritis, kidney fibrosis, and other indications using Bone Morphogenetic Protein (BMP)-7, announced today initial results from the Phase II(a) trial of local BMP-7 administration in patients with moderate osteoarthritis of the knee.

20 Oct 2015

TARSA Therapeutics' TBRIA NDA accepted by FDA for review

TARSA Therapeutics, Inc. today announced that its New Drug Application (NDA) for TBRIATM (calcitonin-salmon [rDNA origin] delayed release tablets) submitted to the U.S. Food and Drug Administration (FDA) in July 2015, has been accepted for review, with a PDUFA date of May 30, 2016.

19 Oct 2015

CNIO researchers identify molecular mechanisms that determine cancer predisposition in DBA patients

Researchers from the Tumour Suppression Group at the Spanish National Cancer Research Centre, headed by Manuel Serrano, have discovered the molecular mechanisms that determine cancer predisposition in patients with Diamond-Blackfan anaemia (DBA).

18 Oct 2015

Researchers explain how incurable type of blood cancer develops

Researchers in the West Midlands have made a breakthrough in explaining how an incurable type of blood cancer develops from an often symptomless prior blood disorder. The findings could lead to more effective treatments and ways to identify those most at risk of developing the cancer.

18 Oct 2015

Study could help mitigate effects of ageing on blood stem cells, promote new therapies for anaemia

A research conducted by Juan Méndez, Head of the DNA Replication Group of the Spanish National Cancer Research Centre (CNIO), sheds light on the molecular mechanisms of ageing of the stem cells responsible for regenerating blood cells and opens up a new avenue for reducing their progressive functional decline with age.

16 Oct 2015

Study suggests combination of MMF and CNIs can protect against rare lymphoma

16 Oct 2015

LifeNet Health's ViviGen Cellular Bone Matrix wins Spine Technology Award

ViviGen Cellular Bone Matrix, an innovative cellular allograft developed by LifeNet Health and marketed in collaboration with DePuy Synthes Spine, received one of the highest honors in spinal medicine, Orthopedics This Week's Best New Technology in Spine award.

15 Oct 2015

Sleep deprivation can impact outcome of stem cell transplantation, study finds

Drowsy mice make poor stem cell donors, according to a new study by researchers at the Stanford University School of Medicine.

15 Oct 2015

Amedica launches innovative articulating inserter for minimally invasive TLIF procedures

Amedica Corporation (Nasdaq:AMDA), a company that develops and commercializes silicon nitride ceramics as a biomaterial platform, is pleased to announce the release of its Scorpion™ articulating inserter to accompany the Valeo II™ TL interbody fusion device system. The Scorpion inserter will be commercially available mid-November 2015, and will aide in minimally-invasive transforaminal lumbar interbody fusion surgeries.

15 Oct 2015

Researchers link organ transplant drug to rise in rare lymphoma

A study led by Johns Hopkins researchers has linked the immunosuppressive drug mycophenolate mofetil (MMF) to an increased risk of central nervous system (CNS) lymphoma in solid organ transplant patients. But the same study also found that another class of immunosuppressive drugs, called calcineurin inhibitors (CNIs), given alone or in combination with MMF, appears to protect transplant patients against this rare form of lymphoma.

15 Oct 2015

DePuy Synthes Spine launches new all-in-one pedicle screw system to help simplify spinal surgery

DePuy Synthes Spine has introduced the EXPEDIUM VERSE Spinal System, a new all-in-one pedicle screw system. The system enables surgeons to perform multiple spinal correction maneuvers during spinal fusion surgery with a single implant type and fewer instruments, compared to traditional pedicle screw systems.

15 Oct 2015

New hope for patients with Duchenne muscular dystrophy

New hope for Duchenne muscular dystrophy (DMD) patients. A mouse genetic study in PLoS Medicine reports that targeting the P2RX7 gene, a purinoreceptor, may halt the progression of DMD.

14 Oct 2015

First-ever genomic study shows dengue may survive year-round in southern China

The first-ever comprehensive genomic analysis of the virus that causes dengue fever suggests that it may survive year-round in southern China.

14 Oct 2015

Researchers identify new therapeutic target for Duchenne muscular dystrophy

Scientists have found what could one day lead to a promising treatment for those with a crippling disease, Duchenne muscular dystrophy.

14 Oct 2015

Blocking the production of CHD4 protein may help increase effectiveness of AML treatments

Preclinical experiments led by a team of researchers at VCU Massey Cancer Center have shown that blocking the production of a protein known as chromodomain helicase DNA-binding protein 4 (CHD4) may help increase the effectiveness of first-line treatments for acute myeloid leukemia (AML), a particularly lethal blood cancer that is increasing in incidence among older adults.

14 Oct 2015

Bone News and Research

High-resolution X-ray method can predict risk of re-operation in patients who receive new hip prosthesis

Melatonin and the circadian rhythm: an interview with Professor Kennaway, University of Adelaide

Viking successfully completes safety, tolerability and pharmacokinetic study of VK5211 in elderly subjects

Mordor Intelligence announces publication of ‘Global Sports Medicine Market’ report

TSRI researchers find way to change leukemia cells into leukemia-killing immune cells

Ember Therapeutics reports initial results from BMP-7 Phase II trial in patients with moderate osteoarthritis of the knee

TARSA Therapeutics' TBRIA NDA accepted by FDA for review

CNIO researchers identify molecular mechanisms that determine cancer predisposition in DBA patients

Researchers explain how incurable type of blood cancer develops

Study could help mitigate effects of ageing on blood stem cells, promote new therapies for anaemia

Study suggests combination of MMF and CNIs can protect against rare lymphoma

LifeNet Health's ViviGen Cellular Bone Matrix wins Spine Technology Award

Sleep deprivation can impact outcome of stem cell transplantation, study finds

Amedica launches innovative articulating inserter for minimally invasive TLIF procedures

Researchers link organ transplant drug to rise in rare lymphoma

DePuy Synthes Spine launches new all-in-one pedicle screw system to help simplify spinal surgery

New hope for patients with Duchenne muscular dystrophy

First-ever genomic study shows dengue may survive year-round in southern China

Researchers identify new therapeutic target for Duchenne muscular dystrophy

Blocking the production of CHD4 protein may help increase effectiveness of AML treatments

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News